Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OTX-TIC low dose Travoprost Intracameral · 1 trial · 2 indications
IOP changes from baseline 8 AM, 10 AM, and 4 PM at Week 2, Week 6, and Week 12 in the study eye.
| Arm | Type | Description |
|---|---|---|
| OTX-TIC Low Dose | EXPERIMENTAL | Travoprost Intracameral Implant low dose |
| OTX-TIC High Dose | EXPERIMENTAL | Travoprost Intracameral Implant high dose |
| Durysta | ACTIVE_COMPARATOR | Bimatoprost Intracameral Implant 10 µg |
| Name | Type | Description |
|---|---|---|
| OTX-TIC low dose Travoprost Intracameral Implant | DRUG | OTX-TIC implant is injected into the anterior chamber of the eye. |
| OTX-TIC high dose Travoprost Intracameral Implant | DRUG | OTX-TIC implant is injected into the anterior chamber of the eye. |
| Durysta, Bimatoprost Intracameral Implant 10 µg | DRUG | Durysta is injected into the anterior chamber of the eye. |
Inclusion Criteria: * Are 18 years of age or older at the time of screening * Provide written informed consent and are able to comply with all study requirements * Are willing to withhold glaucoma medications according to the study requirements, and in the opinion of the investigator can do so with...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |
OTX-TIC low dose Travoprost Intracameral is an investigational small molecule being developed for the treatment of open angle glaucoma. It is administered as an intracameral implant and is currently in Phase 2 clinical development. The drug is designed to deliver travoprost directly into the eye to lower intraocular pressure.
OTX-TIC low dose Travoprost Intracameral contains travoprost, a prostaglandin analog that works by increasing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure. This mechanism is intended to help manage open angle glaucoma by lowering pressure within the eye.
OTX-TIC low dose Travoprost Intracameral is being developed by Ocular Therapeutix, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol OCUL. The company is focused on developing therapies for ophthalmic conditions, including this intracameral implant for open angle glaucoma.
OTX-TIC low dose Travoprost Intracameral is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 2 clinical trial has been completed to evaluate its efficacy and safety in patients with open angle glaucoma or ocular hypertension.
OTX-TIC low dose Travoprost Intracameral has one completed Phase 2 clinical trial, identified as NCT05335122. This randomized, double-blind, active-controlled study enrolled 83 participants in the United States to evaluate the efficacy and safety of the intracameral implant in patients with open angle glaucoma or ocular hypertension.
OTX-TIC low dose Travoprost Intracameral is a formulation of travoprost delivered via an intracameral implant. While travoprost is the active pharmaceutical ingredient, OTX-TIC is a specific sustained-release implant designed to provide low-dose delivery directly into the eye. It is not the same as standard travoprost eye drops.